Jobanputra P, Barton P, Bryan S, Burls A. Efficacy of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. The ACR committee has departed from a list of criteria for the use of biologic therapies in rheumatoid arthritis, reaffirming its position that "the judgment of the individual rheumatologist should be the sole criterion governing access to therapy." Twenty-six weeks - the primary efficacy measure was the total time in weeks that the patient showed a response to therapy as measured by Paulus20.
For convenience, the various versions are referred to as 'the model'; differences between versions are noted as appropriate. LFTs monthly for 6 months, every 8 weeks thereafter Cyclosporin FBC, U&E (x 2), blood lipids, FBC, U&E, BP every 2 weeks until stable dose for 3 months. The latter. These made virtually no difference to the ICERs shown in Table 31 - the point estimate of the ICER for etanercept over base changed from Table 30 Base-case results for BPM.
The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population-based cohort of patients with early inflammatory polyarthritis. The predictive value of the HLA shared epitope for the severity of radiological joint damage in patients with rheumatoid arthritis. A double-blind, placebo-controlled study of the efficacy and safety of four different doses of etanercept in patients with rheumatoid arthritis.
A double-blind, placebo-controlled study of the efficacy and safety of four different doses of etanercept in patients with rheumatoid arthritis: Final report. A double-blind, placebo-controlled study of the efficacy and safety of four different doses of etanercept in patients with rheumatoid arthritis. Assessment of disease activity in RA patients during long-term anti-TNFα treatment.
Evaluation of the disease activity in patients with RA during long-term treatment with anti-TNF. Long-term (1 year) results of a placebo-controlled, randomized phase III, clinical trial of infliximab (cA2, Remicade™) combined with methotrexate in rheumatoid arthritis. Effective combination of the fully human anti-TNF body D2E7 and methotrexate in active rheumatoid arthritis.
Long-term use of the fully human anti-TNF antibody D2E7 in combination with methotrexate in active rheumatoid arthritis. Human anti-chimeric antibody (HACA) responses to infliximab (Remicade™) in the ATTRACT clinical study of patients with active rheumatoid arthritis.
Health Assessment
PLEASE TICK THE ONE ANSWER THAT BEST DESCRIBES YOUR USEFUL ABILITY IN THE PAST WEEK. Add the maximum score for each of the 8 sections and divide by 8 to give a score between 0 and 3. If aid/device or assistance is required, the score for that activity is automatically = 2 (unless 3 is already marked).
Response is defined as ACR20, ACR50, or ACR70, where the numbers refer to percent improvement in the clinical measures shown above.
Assessment of response
ACR revised criteria for
Yield from MEDLINE and
A score of 0 means no narrowing, 1 means minimal narrowing, 2 loss of 50% of joint space, 3 loss of 75% of joint space, and 4 complete loss of joint space. Each hand or wrist joint is scored on a 5-point scale according to the area involved - 0 means no erosion, 5 means extensive bone loss of more than half of the articulating bone. Joint space narrowing is scored in 30 hand and wrist joints and 10 joints in the feet.
A score of 0 indicates no narrowing, a score of 1 is focal or questionable narrowing, 2 is general narrowing of < 50%, 3 is general narrowing of > 50% of the original joint space, and 4 is bony ankylosis or complete luxation.
Notes on radiographic
List of included and
Data combined with other data 44 Kavanaugh et al., 2000106 Yes Placebo-controlled study in 28 patients (infliximab) 45 Kavanaugh et al., 1999209 No Observational study (infliximab). Did not meet inclusion criteria 57 Lukina et al., 1998111 No Did not meet inclusion criteria (new polyclonal anti-TNF agent) 58 Maini et al., 1998114 Yes Phase II study of infliximab. Observational study of muscle function (etanercept) 85 Rankin et al., 1995110 No Did not meet inclusion criteria (anti-TNF agent CDP571).
Etanercept clinical trials
0881A1-301-EU 4-year open-label safety study of etanercept 549 April 1998 Europe patients with rheumatoid arthritis. 0881A1-308-AU/EU A double-blind study evaluating the efficacy to 615* October 2000 Australia, and the safety of the combination of etanercept 19 months Europe, Israel and methotrexate compared to . A randomized trial using magnetic resonance imaging to evaluate the effectiveness of infliximab in combination with methotrexate in patients with early, poor prognosis rheumatoid arthritis.
Infliximab study outcomes
Etanercept study outcomes
University of Bristol Vice-Chancellor, Professor Jon Nicholl, Director, Medical Care Research Unit, University of Sheffield. Professor Douglas Altman, Director, ICRF Medical Statistics Group, University of Oxford Professor John Bond, Director, Center for Health Services Research, University of Newcastle-upon-Tyne. Professor John Brazier, Director of Health Economics, University of Sheffield Dr. Andrew Briggs, Research Fellow.
Institute of Health Sciences, University of Oxford, Christine Clark, Freelance Medical Writer, Bury, Lancs. NHS R&D Clinical Scientist, Institute of Health Sciences, University of Oxford Professor Adrian Grant, direktør, Health Services Research Unit, University of Aberdeen. Institute of Health Sciences, University of Oxford Professor Mark Haggard, direktør, MRC Institute of Hearing Research, University of Nottingham Professor Jenny Hewison, Academic Unit of Psychiatry.
Professor Tim Peters, Social Medicine, University of Bristol Professor Martin Severs, Professor of Aged Health Care. Dr. Sarah Stewart-Brown, Director, Health Services Research Unit, University of Oxford Dr. Gillian Vivian, Consultant in Nuclear Medicine &. Senior Lecturer in General Practice, University of Bristol Dr. Andrew Farmer, GP & NHS R&D Clinical Scientist, Institute of Health Sciences, University of Oxford Professor Jane Franklin, Professor of Medicine, University of Birmingham.
Andrew Walker, Senior Lecturer in Health Economics, University of Glasgow Professor Martin J Whittle, Head of Department of. Professor Terence Stephenson, Professor of Child Health, University of Nottingham Dr Richard Tiner, Medical Director, Association of the British Pharmaceutical Industry, London. Professor John Bond, Professor of Health Services Research, Center for Health Services Research, University of Newcastle-upon-Tyne.
Senior Lecturer in Neurology, University of Aberdeen Dr Keith Dodd, Consultant Paediatrician, Derbyshire Children's Hospital, Derby. Professor James Lindesay, Professor of Geriatric Psychiatry, University of Leicester Professor Rajan Madhok, Medical Director &. Dr Chris McCall, General Practitioner, The Hadleigh Practice, Corfe Mullen, Dorset Professor Alistair McGuire, Professor of Health Economics, London School of Economics, University of London Dr Peter Moore, Freelance Science Writer, Ashtead, Surrey.
